Tetsuya Fujimori
Direktor/Vorstandsmitglied bei Cenegenics Japan KK
Profil
Tetsuya Fujimori is currently the Representative Director at Cenegenics Japan KK since 2020.
Prior to this, he worked as an Independent Outside Director at tella, Inc. Mr. Fujimori completed his undergraduate degree from Osaka City University in 1995.
Aktive Positionen von Tetsuya Fujimori
| Unternehmen | Position | Beginn |
|---|---|---|
Cenegenics Japan KK
 Cenegenics Japan KK Medical SpecialtiesHealth Technology Cenegenics Japan KK engages in the advanced medical support business using genes, cells, and tissues. The company was founded on March 23, 2020 and is headquartered in Tokyo, Japan. | Direktor/Vorstandsmitglied | 01.03.2020 |
Ehemalige bekannte Positionen von Tetsuya Fujimori
| Unternehmen | Position | Ende |
|---|---|---|
| TELLA, INC. | Direktor/Vorstandsmitglied | - |
Ausbildung von Tetsuya Fujimori
| Osaka City University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Cenegenics Japan KK
Cenegenics Japan KK Medical SpecialtiesHealth Technology Cenegenics Japan KK engages in the advanced medical support business using genes, cells, and tissues. The company was founded on March 23, 2020 and is headquartered in Tokyo, Japan. | Health Technology |
tella, Inc.
 tella, Inc. BiotechnologyHealth Technology tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
